1. Bender RA, Zwelling LA, Doroshow JH, Locker GY, Hande KR, Murinson DS, Cohen M, Meyers CE, Chabner A (1978) Antineoplastic drugs: clinical pharmacology and therapeutic use. Drugs 16: 46–51
2. Breithaupt H, Schick J (1981) Determination of cytarabine and uracil arabinoside in human plasma and cerebrospinal fluid by high-performance liquid chromatography. J Chromatogr 225: 99–106
3. Bury RW, Keary PJ (1978) Determination of cytosine arabinoside in human plasma by high-pressure liquid chromatography. J Chromatogr 146: 350–359
4. Capizzi RL, Yang JL, Cheng E, Cheng JC (1983) Pre-clinical and clinical pharmacology of high-dose Ara-C (HiDAC): aspects of “self potentiation” accounting for its unique therapeutic utility. In: 13th Int. Congress of Chemotherapy. Proceedings, Pt 216, pp 13–19
5. lacoboni S, Plunkett W, Keating M, McCredie K, Freireich E (1985) Pharmacologic direction of continuous infusion high dose Ara-C (CIHDAC) for refractory acute leukemia (RAL) and chronic myelogeneous leukemia blast crisis (CML-BC). American Society of Clinical Oncology 4:173, ASCO Abstr 674